What are the primary financial performance indicators to look for in this 10-Q filing?

Investors should focus on the detailed financial statements and the Management's Discussion and Analysis (MD&A) section. The MD&A will provide insights into revenue trends, cost of goods sold, operating expenses, and net income, along with explanations for significant changes. Key performance indicators often include revenue growth, profitability margins, and cash flow generation.

What potential risks or legal issues does Eli Lilly face according to this filing?

The filing explicitly includes sections for 'Legal Proceedings' and 'Risk Factors'. Investors should review these carefully to understand any ongoing litigation, regulatory challenges, patent expirations, competitive pressures, or other factors that could materially affect the company's business, financial condition, or results of operations.

Where can I find information about Eli Lilly's operational performance and strategy?

The 'Management's Discussion and Analysis of Financial Condition and Results of Operations' is the primary section detailing operational performance. It will discuss the company's business segments, product performance, R&D pipeline, and strategic initiatives, providing context for the financial results.

Are there any forward-looking statements in this filing that I should be aware of?

Yes, the 'Cautionary Statement Regarding Forward Looking Statements' within the 'Risk Factors' section typically addresses forward-looking statements. This section outlines the inherent uncertainties and risks associated with projections and management's expectations about future performance.

LLY 10-Q Quarterly Report Q1 FY2010 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's (LLY) 10-Q filing for the period ending March 30, 2010, indicates a company navigating a dynamic pharmaceutical landscape. While specific financial figures are not detailed in the provided excerpt, the filing structure suggests a comprehensive review of the company's performance and operational status. Investors should pay close attention to the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for insights into revenue drivers, cost management, and any significant operational changes during the quarter. The inclusion of 'Legal Proceedings' and 'Risk Factors' also signals potential challenges or uncertainties that could impact future performance and shareholder value.

Financial Highlights

46 data points

Beta

Revenue

$5.49B

0.8% Gross Margin

Net Income

$1.25B

0.2% Net Margin

EPS (Diluted)

$1.13

Total Assets

$27.20B

Cash & Equivalents

$4.73B

Free Cash Flow

$958.00M

Financial Statements

Beta

Revenue	$5.49B
Cost of Revenue	$1.12B
Gross Profit	$4.36B
R&D Expenses	$1.04B
SG&A Expenses	$1.61B
Interest Expense	$47.60M
Net Income	$1.25B
EPS (Basic)	$1.13

Key Highlights

1The filing covers the quarterly period ending March 30, 2010, providing a snapshot of Lilly's financial and operational health.
2Key sections include Financial Statements, Management's Discussion and Analysis, and Controls and Procedures, crucial for understanding performance and internal controls.
3Attention should be given to 'Legal Proceedings' as these can represent significant financial or reputational risks.
4The 'Risk Factors' section is vital for understanding potential headwinds and uncertainties affecting the company's future outlook.
5The filing indicates the company is adhering to SEC reporting requirements for public companies.
6This report is a key document for assessing the company's near-term financial trajectory and strategic positioning.

ELI LILLY & Co Quarterly Report for Q1 Ended Mar 31, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions